Summary of select differences between human VWF, VWF/FVIII concentrates, and rVWF
| Characteristics of rVWF . | Comments . |
|---|---|
| Carbohydrate structure/glycosylation pattern | Similar to human platelet VWF and lacking ABO antigens |
| Ultra large multimers | Intact UL-HMW from lack of ADAMTS13 exposure in processing before infusion |
| Multimer triplet pattern | Intact multimer pattern from lack of exposure to ADAMTS13 during processing, forms triplet pattern in vivo |
| Performance in VWF functional assays | Functional activity of rVWF similar with regard to VWF:FVIIIB but higher in VWF:RCo and VWF:CB and VWF:RCo/VWF:Ag >1 indicating higher VWF specific activity |
| Platelet adhesion/aggregation assay results | No evidence of exaggerated or activation independent platelet binding despite presence of UL-HMW multimers. Reduced closure times consistently of PFA-100 compared with pdVWF |
| Characteristics of rVWF . | Comments . |
|---|---|
| Carbohydrate structure/glycosylation pattern | Similar to human platelet VWF and lacking ABO antigens |
| Ultra large multimers | Intact UL-HMW from lack of ADAMTS13 exposure in processing before infusion |
| Multimer triplet pattern | Intact multimer pattern from lack of exposure to ADAMTS13 during processing, forms triplet pattern in vivo |
| Performance in VWF functional assays | Functional activity of rVWF similar with regard to VWF:FVIIIB but higher in VWF:RCo and VWF:CB and VWF:RCo/VWF:Ag >1 indicating higher VWF specific activity |
| Platelet adhesion/aggregation assay results | No evidence of exaggerated or activation independent platelet binding despite presence of UL-HMW multimers. Reduced closure times consistently of PFA-100 compared with pdVWF |
CB, collagen binding; PFA-100, platelet function analyzer; UL HMW, ultralarge high-molecular-weight multimers. Summarized data from Franchini et al62 and Turecek et al.63